New pill could reduce Blood-Letting for rare blood cancer patients

NCT ID NCT05558696

Completed Disease control Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy) for at least 12 weeks. Participants who benefited could continue treatment for up to a year. The study is complete, and results will show whether bomedemstat is a promising new option for controlling this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bomedemstat (oral capsule)

What this could lead to

If successful, bomedemstat could offer a new oral treatment option to control red blood cell levels in people with polycythemia vera, reducing the need for blood removal procedures.

What could go wrong

This is a small, early-phase study (20 participants) focused on safety and short-term effects. The drug may not work in larger groups or could cause side effects. Long-term benefits are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA

Contacts and locations

Show contact details

Locations

BRCR Global ( Site 0120)

Plantation, Florida, 33322, United States
Boston Pilgrim Hospital ( Site 0207)

Boston, Lincolnshire, PE21 9QS, United Kingdom
Comprehensive Cancer Centers of Nevada - Peak ( Site 0118)

Las Vegas, Nevada, 89128, United States
Duke University Medical Center ( Site 0016)

Durham, North Carolina, 27705, United States
Gloucestershire Royal Hospital ( Site 0205)

Gloucester, England, GL1 3NN, United Kingdom
Guys and St Thomas NHS Foundation Trust - Guys Hospital ( Site 0020)

London, London, City of, SE1 9RT, United Kingdom
Hematology Oncology of the North Shore ( Site 0104)

Skokie, Illinois, 60076-1264, United States
Huntsman Cancer Hospital at the University of Utah ( Site 0119)

Salt Lake City, Utah, 84112, United States
Imperial College London ( Site 0025)

London, Great Britain, W12 0HS, United Kingdom
Monash Medical Centre ( Site 0006)

Clayton, Victoria, 3168, Australia
OHSU Knight Cardiovascular Institute Cardiology Clinic - South Waterfront ( Site 0102)

Portland, Oregon, 97239-4503, United States
Ohio State University Comprehensive Cancer Center ( Site 0103)

Columbus, Ohio, 43203, United States
Royal Gwent Hospital ( Site 0201)

Newport, Wales, NP9 2UB, United Kingdom
Royal Perth Hospital ( Site 0504)

Perth, Western Australia, 6000, Australia
Sunshine Coast Hematology and Oncology Clinic (Site 0506)

Sunshine Coast, Queensland, 4556, Australia
United Lincolnshire Hospitals NHS Trust ( Site 0204)

Lincoln, Great Britain, LN2 5QY, United Kingdom
University of Michigan Comprehensive Cancer Center ( Site 0008)

Ann Arbor, Michigan, 48109, United States